{"title":"feprazone治疗后肝损伤。","authors":"J Wiggins, D L Scott","doi":"10.1093/rheumatology/20.1.44","DOIUrl":null,"url":null,"abstract":"<p><p>Two cases of feprazone-induced hepatic injury are reported. Both patients developed jaundice within one month of commencing therapy. Histological investigation showed a granulomatous reaction in one case and hepatitic changes in the other. The changes were similar to those seen as a complication of phenylbutazone therapy. When the administration of feprazone was discontinued both the clinical and biochemical changes were resolved.</p>","PeriodicalId":76486,"journal":{"name":"Rheumatology and rehabilitation","volume":"20 1","pages":"44-5"},"PeriodicalIF":0.0000,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/rheumatology/20.1.44","citationCount":"4","resultStr":"{\"title\":\"Hepatic injury following feprazone therapy.\",\"authors\":\"J Wiggins, D L Scott\",\"doi\":\"10.1093/rheumatology/20.1.44\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Two cases of feprazone-induced hepatic injury are reported. Both patients developed jaundice within one month of commencing therapy. Histological investigation showed a granulomatous reaction in one case and hepatitic changes in the other. The changes were similar to those seen as a complication of phenylbutazone therapy. When the administration of feprazone was discontinued both the clinical and biochemical changes were resolved.</p>\",\"PeriodicalId\":76486,\"journal\":{\"name\":\"Rheumatology and rehabilitation\",\"volume\":\"20 1\",\"pages\":\"44-5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/rheumatology/20.1.44\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rheumatology and rehabilitation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/rheumatology/20.1.44\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology and rehabilitation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/rheumatology/20.1.44","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Two cases of feprazone-induced hepatic injury are reported. Both patients developed jaundice within one month of commencing therapy. Histological investigation showed a granulomatous reaction in one case and hepatitic changes in the other. The changes were similar to those seen as a complication of phenylbutazone therapy. When the administration of feprazone was discontinued both the clinical and biochemical changes were resolved.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
